EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY... by Davies, J, Gill, D, Griesenbach, U, Voase, N, Davies, G, Higgins, T, Innes, J, Boyd, C, Porteous, D, Hyde, S, Alton, E

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM... by Davies, J, Davies, G, Voase, N, Hyde, S, Innes, A, Boyd, C, Porteous, D, Higgins, T, Griesenbach, U, Gill, D, Alton, E

UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation by Gray, R, Horsley, A, Macleod, K, Imrie, M, Dewar, M, Voase, N, Donovan, J, Hyde, S, Gill, D, Griesenbach, U, Davies, J, Alton, E, Boyd, A, Porteous, D, Cunningham, S, Innes, J, Greening, A

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. by Horsley, A, Davies, J, Gray, R, Macleod, K, Donovan, J, Aziz, Z, Bell, N, Rainer, M, Mt-Isa, S, Voase, N, Dewar, M, Saunders, C, Gibson, J, Parra-Leiton, J, Larsen, MD, Jeswiet, S, Soussi, S, Bakar, Y, Meister, MG, Tyler, P, Doherty, A, Hansell, D, Ashby, D, Hyde, S, Gill, D

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation by Horsley, A, Davies, J, Gray, R, MacLeod, K, Donovan, J, Aziz, Z, Bell, N, Rainer, M, Mt-Isa, S, Voase, N, Dewar, M, Saunders, C, Gibson, J, Parra-Leiton, J, Larsen, MD, Jeswiet, S, Soussi, S, Bakar, Y, Meister, MG, Tyler, P, Doherty, A, Hansell, D, Ashby, D, Hyde, S, Gill, DR